Skip to main content
Kusurinomadoguchi, Inc. logo

Kusurinomadoguchi, Inc. — Investor Relations & Filings

Ticker · 5592 ISIN · JP3266230006 T Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 26 across all filing types
Latest filing 2024-06-27 Annual Report
Country JP Japan
Listing T 5592

About Kusurinomadoguchi, Inc.

https://kusurinomadoguchi.co.jp/

Kusurinomadoguchi, Inc. develops and provides a comprehensive suite of technology-driven solutions for the healthcare and pharmaceutical sectors. The company operates a platform connecting patients with pharmacies and medical institutions, while also offering extensive support services for healthcare providers. Its primary consumer-facing service, 'EPARK Kusuri no Madoguchi,' is a large-scale pharmacy search and online prescription reservation portal, complemented by the 'EPARK Okusuri Techo' digital medication management application. For pharmacies and medical facilities, the company provides solutions to enhance operational efficiency, including integrated systems for patient management, POS systems, procurement support, a matching platform for surplus medication, dispensing audit systems, and AI-powered voice recognition for automating clinical documentation.

Recent filings

Filing Released Lang Actions
有価証券報告書－第20期(2023/04/01－2024/03/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, management discussion and analysis, and corporate information for the fiscal year ending March 31, 2024. It is filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2024
2024-06-27 Japanese
臨時報告書
M&A Activity Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau. Section 1 explicitly states the reason for filing: "当社において、特定子会社の異動が生じましたので...提出するものであります" (Because there has been a change in a specified subsidiary of our company, we are submitting this report...). Section 2 details the change, specifically the acquisition of 100% of the voting rights in a subsidiary (株式会社ＥＰＡＲＫ人間ドック), making it a specified subsidiary. This type of filing in Japan, reporting a significant event like a change in subsidiary status, often corresponds to a filing that reports a major transaction or change in control/ownership structure. Given the options, this document reports a significant corporate event (change in subsidiary status due to acquisition) that is not a standard periodic report (10-K, IR) or a simple management change (MANG). It is a specific regulatory disclosure regarding ownership structure change. While it relates to M&A activity (TAR), the primary purpose here is the formal notification of the resulting change in subsidiary status as required by financial regulations, which often falls under general regulatory filings or specific transaction reports. Since the core event is the change in subsidiary status due to an acquisition, and it is a formal, non-periodic disclosure, it aligns best with a general regulatory filing or a transaction report. However, the structure strongly suggests a mandatory disclosure of a significant event, which in many contexts is captured by the general regulatory filing category if a more specific code isn't available. Given the options, 'TAR' (M&A Activity) is relevant because an acquisition caused this, but 'RNS' (Regulatory Filings) is the most appropriate fallback for mandatory, non-standard disclosures like this specific change in subsidiary status report (which is often filed using a specific Japanese form like a 'Tōkigen-Hōkoku-sho' or similar, which maps best to a general regulatory filing if not covered elsewhere). Since the document details the acquisition and the resulting change in subsidiary status, and it is a formal report, I will classify it as a general Regulatory Filing (RNS) as it is a mandatory disclosure of a significant corporate event not explicitly covered by other codes like ER, 10-K, or DIV. The document length is short, but it is the report itself, not an announcement of a report, so RPA is incorrect. RNS is the best fit for this type of mandatory, non-periodic disclosure.
2024-06-05 Japanese
臨時報告書
M&A Activity Classification · 1% confidence The document is explicitly titled "【提出書類】臨時報告書" (Filing Document: Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director. The content details a resolution made by the Board of Directors on June 5, 2024, regarding an absorption-type merger where the company will absorb its specific subsidiary, Hospital Healthcare Co., Ltd., effective November 1, 2024. This type of filing, reporting significant corporate actions like mergers, capital structure changes, or major events outside of routine periodic reports (like 10-K or IR), is typically classified as a special or extraordinary report in Japanese regulatory contexts. Given the provided definitions, this relates to a significant corporate transaction (merger/acquisition) and is not a standard 10-K, ER, or IR. Since it details a major corporate action (merger) and is an extraordinary filing, it most closely aligns with a significant corporate event disclosure. While 'TAR' (M&A Activity) is related, the document structure and explicit mention of "臨時報告書" (Extraordinary Report) often map to a general regulatory disclosure category when a more specific one isn't perfectly defined for this exact form type. However, since the core event is an absorption merger, 'TAR' (M&A Activity) is the most relevant specific category among the choices, as it covers merger proposals/takeover bids. Given the context of Japanese filings, '臨時報告書' often falls under general regulatory disclosures, but the content is clearly M&A related. I will classify it as TAR based on the content (merger) and assign a high confidence score due to the explicit nature of the transaction described.
2024-06-05 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is extremely short (598 characters) and contains a table structure typical of a cover page for a regulatory filing, specifically mentioning '【提出書類】確認書' (Document Submitted: Confirmation Document) and referencing the Financial Instruments and Exchange Act ('金融商品取引法'). The main body confirms that the President and CFO have verified the appropriateness of the '第20期第３四半期（自2023年10月１日 至2023年12月31日）の四半期報告書' (Quarterly Report for the 3rd Quarter of the 20th Period). Since this document is a confirmation/attestation regarding a Quarterly Report, and not the comprehensive Quarterly Report itself, it fits best under the category for regulatory filings that confirm compliance or attest to information. Given the options, this confirmation document related to a quarterly report is a specific type of regulatory filing. However, none of the codes explicitly cover a 'Confirmation Document' or 'Attestation'. The closest related document type is the Interim/Quarterly Report (IR), but this is the *confirmation* of the IR. Since it is a formal regulatory submission confirming accuracy, and it is not an announcement of a report release (RPA) or a general miscellaneous filing (RNS), I must re-evaluate. The content is a formal declaration of accuracy regarding a quarterly filing. This type of document often accompanies or is filed in lieu of a full report when specific attestations are required. Given the limited choices, and recognizing that this is a formal regulatory submission related to quarterly financials, it is most closely related to the Interim/Quarterly Report (IR) category, but since it is an attestation, it is a specific regulatory filing. If we strictly follow the definitions, it is a formal regulatory document. Since it is not an ER (Earnings Release - highlights only) or IR (Comprehensive report), and it is a formal submission, 'RNS' (Regulatory Filings - general fallback) is the safest classification for a specific, non-listed regulatory document type, although 'IR' is the subject matter. Given the structure and purpose (confirmation of a quarterly report), it is a specific regulatory filing. I will classify it as RNS as it is a specific regulatory confirmation document not covered by other codes, adhering to the principle that specific attestations often fall into the general regulatory bucket if a specific code for 'Attestation' is missing.
2024-02-14 Japanese
四半期報告書－第20期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the consolidated balance sheet, income statement, and comprehensive income statement for the third quarter of the 20th fiscal year (April 1, 2023, to December 31, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. 9M 2024
2024-02-14 Japanese
臨時報告書
Major Shareholding Notification Classification · 1% confidence The document is a Japanese regulatory filing, indicated by headers like '【提出書類】 臨時報告書' (Filing Document: Extraordinary Report) and '【提出先】 関東財務局長' (Filing Recipient: Director of the Kanto Local Finance Bureau). The content explicitly discusses a change in a specific subsidiary ('特定子会社の異動'), detailing the acquisition of 100% voting rights in '株式会社ホスピタルヘルスケア' (Hospital Healthcare Co., Ltd.). This type of filing, reporting a significant change in control or ownership structure (like making a company a wholly-owned subsidiary), is typically classified as a major corporate event disclosure. In the provided schema, while there isn't a direct 'Change in Control' code, the closest fit for a mandatory, non-periodic, significant corporate event disclosure that isn't M&A (TAR) or Director's Dealing (DIRS) is often captured under general regulatory filings or specific event types. Given the nature of reporting a change in subsidiary status based on financial thresholds (implied by the voting rights change), this strongly aligns with mandatory disclosure requirements for significant corporate structure changes. Since the document reports a specific transaction leading to a change in subsidiary status, and it is an 'Extraordinary Report' (臨時報告書), it is a specific regulatory disclosure. The closest category that covers significant, non-standard corporate actions that require immediate reporting, especially when related to ownership structure changes that aren't M&A bids, is often grouped under general regulatory filings if a more specific code isn't available. However, the core event is a change in ownership/control leading to a subsidiary status change. Given the options, and recognizing this as a mandatory disclosure of a significant corporate event, 'RNS' (Regulatory Filings - general fallback) is appropriate, although 'CAP' (Capital/Financing Update) or 'TAR' (M&A) are related, this is specifically about subsidiary status change. Since the document is the report itself (not an announcement of a report), and it details a significant corporate structure change, 'RNS' serves as the best fit among the provided codes for a mandatory, non-periodic disclosure not covered elsewhere.
2023-12-22 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.